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Preterm and young neonates have an increased predisposition to respiratory distress syndrome (RDS)
associated with an immature development of lung surfactant. Glucocorticoids (GCs) are the major
immunomodulatory agents used to increase lung development and reduce the mortality and morbidity of
preterm infants with RDS. However, their safety remains uncertain, and the precise mechanisms by which
they improve lung function are unclear. In previous studies, we found that vascular endothelial growth factor
(VEGF) enhances the innate immune response by respiratory epithelial cells, causes a monocytic infiltration
into the lung, and reduces the severity of infection by respiratory syncytial virus (RSV), a respiratory
pathogen known to affect preterm infants at a high prevalence. The purpose of this study is to measure the
effects of VEGF administration on local immune responses in neonatal lambs, as the ovine lung is well suited
for comparison to the human lung, due to similarities in alveolar development, immune responses, and RSV
susceptibility. We hypothesized that VEGF induces the expression of genes necessary for host immune
responses. We analyzed global gene expression profiles in the lungs of neonate lambs treated with VEGF by
real-time qPCR. We report that VEGF induced the expression of chemokines (IL-8, RANTES, MCP-1),
cytokines (IFN-γ, IL-6, TNF-α, GMCSF), Toll-like receptor (TLR)-4, complement family members (C3,
CFB, CFH) and collectins (SP-A, SP-D). These results suggest that VEGF can regulate local immune gene
expression in vivo and should be further explored as a potential exogenous therapy for various lung diseases.
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Abstract
Preterm and young neonates have an increased predisposition to respiratory distress syndrome (RDS)
associated with an immature development of lung surfactant. Glucocorticoids (GCs) are the major
immunomodulatory agents used to increase lung development and reduce the mortality and morbidity
of preterm infants with RDS. However, their safety remains uncertain, and the precise mechanisms
by which they improve lung function are unclear. In previous studies, we found that vascular
endothelial growth factor (VEGF) enhances the innate immune response by respiratory epithelial
cells, causes a monocytic infiltration into the lung, and reduces the severity of infection by respiratory
syncytial virus (RSV), a respiratory pathogen known to affect preterm infants at a high prevalence.
The purpose of this study is to measure the effects of VEGF administration on local immune responses
in neonatal lambs, as the ovine lung is well suited for comparison to the human lung, due to similarities
in alveolar development, immune responses, and RSV susceptibility. We hypothesized that VEGF
induces the expression of genes necessary for host immune responses. We analyzed global gene
expression profiles in the lungs of neonate lambs treated with VEGF by real-time qPCR. We report
that VEGF induced the expression of chemokines (IL-8, RANTES, MCP-1), cytokines (IFN-γ, IL-6,
TNF-α, GMCSF), Toll-like receptor (TLR)-4, complement family members (C3, CFB, CFH) and
collectins (SP-A, SP-D). These results suggest that VEGF can regulate local immune gene expression
in vivo and should be further explored as a potential exogenous therapy for various lung diseases.
Keywords
Preterm infant; Neonate; Lung; Vascular endothelial growth factor; Immune response; Respiratory
distress syndrome; Macrophage; Epithelial cell
1. Introduction
Respiratory distress syndrome (RDS) is a respiratory condition affecting 1% of newborn infants
and is a significant cause of preterm infant mortality in the US [1,2]. The development of RDS
is attributed to the developmental immaturity [3] and to the insufficiency of surfactant
production of the neonatal lung. The incidence of RDS disease increases with low birth weight
[4] but decreases with advanced gestational age [5]. An immature immune system, low birth
weight, lung and airway immaturity, and impaired lung epithelial cell regeneration of neonates
with RDS are all factors that may contribute to increased disease susceptibility to respiratory
pathogens such as respiratory syncytial virus (RSV).
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The study of human fetal-neonatal development requires the use of animal models with similar
gestation to humans [6]. Although humans are phylogenetically closer to rodents than sheep
[7], the ovine perinatal lung has more similarity to the human lung. In contrast to rodents,
alveolar development in humans and lambs occurs prenatally [6,8]. Alveoli, distal bronchioles
and respiratory epithelia are also similar in morphology and Clara cell numbers in humans and
lambs, whereas mouse bronchioles have a large population of Clara cells. Also, human and
ovine airways possess submucosal glands, which are not present in rodents and are critical for
the innate immune response through the production of lactoperoxidase (LPO) and the NADPH
oxidases (duox1 and duox2) [9–11].
Infants suffering from RDS often require mechanical ventilation and receive prophylactic and
surfactant replacement therapy to reduce complications. Although surfactant and
corticosteroids have decreased the mortality associated with respiratory problems in newborn
infants [12,13], it has been suggested that both ventilation and treatment with surfactant can
be risk factors for bronchopulmonary dysplasia (BPD) [14], while corticosteroids are
associated with other adverse effects.
Glucocorticoids (GCs) are frequently used as prophylactic treatments to enhance the
maturation of lungs in infants and minimize the adverse effects of preterm birth [12]. However,
while repeated doses of prenatal betamethasone benefit lung function in animals, it also has
adverse effects on neuronal myelination [15], hypothalamic–pituitary–adrenal function [16],
and fetal growth [17]. In human infants, repeated corticosteroid administration was associated
with neuronal [18] and developmental [19] problems as well as an increased risk for neonatal
infection [19]. Also, the precise mechanisms by which GCs enhance lung function are
unknown. As the efficacy and safety of GCs remain uncertain, the search for novel, safer
surfactant replacement therapies is a priority.
Recent efforts in finding new therapeutic agents for lung maturation have pointed at vascular
endothelial growth factor (VEGF) as a potential candidate. VEGF is an immunoregulator and
a growth factor, responsible for mediating angiogenesis and vascular permeability [20,21].
VEGF is vital for lung development, and alterations in its expression are associated with
chronic lung disease/bronchopulmonary dysplasia [22,23]. VEGF binds two receptors,
VEGFR1 (also called Flt-1) and VEGFR2 (also called Flk-1 or KDR). VEGFR1 is induced by
hypoxia and induces hematopoiesis, monocyte migration, recruitment of endothelial
progenitors, and the induction of other growth factors. VEGFR2 induces endothelial cell
proliferation, migration and survival. VEGF is a critical factor in embryonic and postnatal
development of the vasculature, and recent evidence suggests that vascular development drives
pulmonary alveolar development [22,24].
Previously, we have shown that although exogenous VEGF can induce leukocyte recruitment
to the lung in a dose-dependent manner [25], in lower non-inflammatory doses, VEGF can
reduce the severity of disease caused by RSV in the lungs of newborn lambs [26]. The precise
mechanisms by which VEGF induces monocytic chemotaxis and inhibits viral replication are
currently unknown. Because VEGF has been implicated in pivotal roles related to lung
development, we reasoned that VEGF may enhance lung immunity through the induction of
cytokines, chemokines and activation of growth factor pathways. We performed an in vivo
quantitative global gene expression study of the effects of VEGF on genes involved in innate
and adaptive immune responses central to RSV infection in the lungs of full-term lambs that
did not have RDS. To support the role of VEGF in lung immune functions, we tested two
hypotheses: (1) VEGF regulates numerous genes that play critical roles in innate and adaptive
immune responses; and (2) VEGF is an immune-enhancing agent.
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2. Materials and methods
2.1. Animals
Animal use and all experimental procedures were approved by Iowa State University’s Animal
Care and Use Committee. The lambs in this study were the same animals used previously to
characterize the bronchoscopic deposition of VEGF in the lungs of neonatal lambs [25]. The
study was conducted in full-term lambs that did not have RDS. Briefly, healthy male and female
neonatal lambs at 2–4 days of age (see [25]) were randomly assigned to three groups: a saline-
inoculated group (n = 3), a VEGF-inoculated group (for low dose VEGF n = 1 at all time points;
for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h; for high dose VEGF, n
= 1 for all time points), and a bovine serum albumin (BSA)-inoculated group (n = 2). Lambs
were sedated with xylazine (0.1 mg/kg) intravenously (i.v.), and a sterile bronchoscope was
used to instill 10 ml of sterile saline, BSA, or recombinant human VEGF165 (0.05, 0.005, 0.0005
mg/ml; endotoxin <100 pg/μg in stock solution; diluted with sterile saline solution pH 7.0;
Invitrogen, Carlsbad, CA) in the right mainstem bronchus. Human VEGF165 and ovine
VEGF164 are 93.3 % identical at the amino acid level. Lambs were euthanized with sodium
pentobarbital i.v. after 16, 24, or 32 h after inoculation. Lungs were removed, snap frozen in
liquid nitrogen, and stored at −80 °C. Lung tissue from the inoculated side (right lung) was
used for all experiments in this study.
2.2. RNA isolation
Total RNA was isolated from the inoculated right lung as follows: lungs were weighed and
homogenized in 3 ml of TRIzol reagent (Invitrogen, Carslbad, CA) using an Omni TH
homogenizer (Omni International, Marietta, GA). A portion of the homogenized lungs was
further diluted in TRIzol to obtain a 0.0909 g of tissue/ml homogenate. The homogenate was
vortexed, and nuclease-free chloroform was added to each sample, mixed, and spun at 12,000
× g for 10 min. The aqueous layers were transferred into microfuge tubes containing nuclease-
free 2-propanol (Fisher Chemical, Fairlawn, NJ). The pellets obtained after centrifugation
(12,000 × g for 10 min) were washed twice in ice-cold 75% nuclease-free ethanol, after which
the supernatant was removed, and the pellets were allowed to air-dry. The pellets were
resuspended in nuclease-free 0.1 mM EDTA, pH 7.0 and were heated at 65 °C for 5 min for
better dissolution. RNA was diluted at 1:50, and concentrations and purity were determined
by absorbance readings at 260 and 280 nm. The RNA samples were further subjected to DNase
treatment using TURBO DNase (TURBO DNA-free kit, Ambion, Austin, TX). Eighty
microliters of each RNA sample was recovered after DNase treatment and further diluted 1:10
with nuclease-free water (Ambion) and RNaseOUT (Invitrogen) for one-step qPCR use.
2.3. One-step real-time qPCR
Prior to final qPCR sample analyses, a test plate was run (using a mixture of RNA samples
serially diluted from full-strength to 1:100,000 in-well) for each target of interest to identify
(1) the specific RNA sample dilution range at which qPCR inhibition no longer existed; and
(2) the extended dilution range of the standard curves within which all targets exhibited
amplification efficiencies between 80 and 100%. Test plate set-up parameters and analysis
were performed using PREXCEL-Q (P-Q) [27]. The threshold of sample-related inhibition
was subsequently found to be 1:290 in-well, and all target standard curves were found to share
the same optimal RNA dilution range of 1:400 to 1:8000 in-well. Five point standard curves
were generated for each target in that range and the 1:10 RNA samples were diluted to their
ideal concentration of 3.268 ng/μl that, when added to the final reaction mixtures for qPCR,
arrives at the calculated ideal concentration for each RNA within the valid standard curve range
for each target.
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The optimally-diluted RNA samples were used as “RNA templates” in 20 μl fluorogenic one-
step real-time qPCR reactions containing the RNA samples (ending up at 0.7844 ng total RNA/
μl in all final qPCR reactions), 775 nM forward and reverse primers (see Table 1 for primer
and probe sequences and [28]), 150 nM TaqMan probe (either 5′-6FAM, 3′-TAMRA-quenched
or 5′-6FAM, 3′-MGBNFQ probes used), nuclease-free water, and the following reagents from
the SuperScript™ III Platinum® One-Step quantitative RT-PCR System with ROX kit
(Invitrogen, Carlsbad, CA): 5.5 mM MgSO4, SuperScript III RT/Platinum Taq mix, and one-
step qPCR SuperMix containing 1 μM ROX. RNA samples, negative no-template controls,
and standards were placed in duplicate wells of a 96-well qPCR reaction plate (Applied
Biosystems, Forest City, CA) and were run in the GeneAmp 5700 Sequence Detection System
(Applied Biosystems) for detection and relative quantification of targets at 15 min 55 °C, 2
min 95 °C, and 50 cycles of 15 s 95 °C, 30 s 58 °C.
The resulting Ct values were gathered at an appropriate threshold for each different target using
the GeneAmp 5700 SDS software, and relative quantitative analysis was performed using our
own custom Excel files. Relative mRNA expression quantity for each qPCR target was
calculated using the equation: relative quantity = 10(Ct−b)/m (or ). Final relative values
normalized to control values were calculated using the efficiency-corrected comparative
quantitative method (  method), which is identical to the 2−ΔCt or 2ΔCt (depending on the
directionality of Ct subtraction) comparative quantitative method when target amplification
efficiencies are assumed to be ~100% [29]. Relative quantity values for each target were thus
calculated from each sample’s target mRNA Ct (generated at 0.7844 ng/μl in-well total RNA
concentration) using the slope (m) and y-intercept (b) of the line generated for each target’s
standard curve. qPCR amplification efficiency (E) and exponential amplification (EAMP)
values were determined from the slope of the line (which is a plot of Ct versus log10 of 1/
dilution factor). qPCR values E and EAMP were determined from the slope of the line using
the relationships: E = 10−1/m − 1 and EAMP = E + 1 (or 10 −1/m), respectively. The slope of the
line can also be expressed as: m = −1/log10(EAMP). Using the efficiency-corrected comparative
quantitative  expression: , averaged individual (relative) target
values were normalized to their averaged group control (relative) target values. It is worth
mentioning here that P-Q is a new Excel-based software program [27], which provides a careful
approach to qPCR, and which has recently been endorsed by Dr. Stephen A. Bustin, an
acknowledged leader in use of qPCR theory and methodology.
2.4. Statistical analysis
The results were analyzed by one-way ANOVA using SAS version 9.1 (SAS Institute, Cary,
NC). Mean values of relative mRNA expression levels of VEGF-treated animals, saline-treated
animals and BSA-treated animals were compared at *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001
and expressed as means ± SEM.
3. Results
3.1. Effect of VEGF on chemokine expression in the newborn lung
To address the effect of VEGF on local lung immunity, we first sought to investigate the effect
of VEGF on the mRNA expression levels of chemokines. Fig. 1 shows that VEGF mediates
the induction of IL-8, RANTES and MCP-1. In contrast to saline-treated animals, animals
treated with the high dose VEGF (0.05 mg/ml) had an impressive increase in IL-8 mRNA at
all time points studied (16, 24, and 32 h; Fig. 1A). RANTES mRNA showed a trend towards
increased expression at 16 h, but was significantly decreased at 24 h with the high dose VEGF
(Fig. 1B). However, at 32 h, the levels increased rapidly again, with an 8.02-fold increase in
mRNA level seen in animals treated with the low dose VEGF (0.0005 mg/ml) and a 4.24-fold
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increase in animals treated with the medium dose VEGF (0.005 mg/ml). Because monocytes
and macrophages were the main cells recruited to the lung following VEGF administration,
we next looked at the expression levels of MCP-1, a chemotactic factor for these cells. The
highest dose of VEGF decreased MCP-1 levels at 16 and 24 h (Fig. 1C). However, MCP-1
levels were higher than control animals at 32 h after treatment with all doses of VEGF,
indicating that any dose of VEGF was sufficient to induce MCP-1 expression in the lung of
treated animals. The expression level of the co-stimulatory molecule ICAM-1 was also
measured but was not significantly affected by VEGF (data not shown). Animals treated with
BSA had no statistically significant changes in gene expression at 32 h relative to saline-treated
animals. Thus, VEGF is a potent stimulator of chemokines in the neonatal ovine lung.
3.2. Effect of VEGF on inflammatory mediators in the lung
We next investigated the effects of VEGF administration on the expression levels of pro-
inflammatory cytokines/mediators in the lung. Similarly to MCP-1 (Fig. 1C), IFN-γ mRNA
levels were unaffected by VEGF at 16 and 24 h after treatment (Fig. 2A). However, in animals
treated for 32 h with VEGF, IFN-γ levels increased significantly compared to saline-treated
animals. The lowest dose of VEGF induced a 4.61-fold increase in IFN-γ mRNA. IL-6 is also
a marker of a pro-inflammatory response. IL-6 mRNA levels were mostly increased in animals
treated with VEGF for 32 h (Fig. 2B). Increases in TNF-α mRNA levels also coincided with
the accumulation of macrophages to the lungs, at 32 h after stimulation with VEGF (Fig. 2C).
The lowest dose of VEGF was sufficient to significantly induce TNF-α at this time point.
Interestingly, TNF-α was significantly decreased by VEGF treatment at 16 and 24 h. As GCs
were shown to inhibit the expression of many inflammatory molecules [30], including IFN-β
and GMCSF in a human epithelial cell line [31], we also sought to examine the effects of VEGF
on these inflammatory mediators. We found that VEGF significantly decreased the expression
of IFN-β regardless of the dose or time (Fig. 2D), but not that of GMCSF (Fig. 2E). Animals
treated with BSA had no statistically significant alterations in gene expression, expect when
IFN-β was assessed, possibly due to animal to animal variations. Thus, the administration of
VEGF in the lung environment has differential effects on the expression levels of inflammatory
molecules.
3.3. Role of VEGF in the expression levels of complement factors
The activation of the complement system forms the first line of defense against invading
pathogens and causes the release of complement factors. Previous studies have reported the
ability of human bronchial epithelium [32], type II alveolar cells [33] and lung fibroblasts
[34] to generate complement. We observed that in the lung, C3 (Fig. 3A), CFB (Fig. 3B), and
CFH (Fig. 3C) were decreased by VEGF treatment during the early time points (16 and 24 h),
but were all induced at 32 h in VEGF-treated animals, regardless of the dose used.
3.4. VEGF induces the expression levels of TLR4
An invasion of microorganisms can be sensed in mammals by TLR family members,
culminating in the activation of a range of host defense mechanisms. We found that TLR4 was
inhibited in animals treated with VEGF for 16 and 24 h, but that it was significantly increased
at 32 h with all doses of VEGF (Fig. 4).
3.5. The expression of anti-inflammatory cytokines is delayed in the lung
The net effect of an inflammatory response is determined by the balance between pro-
inflammatory cytokines and anti-inflammatory cytokines. Cytokines such as TGF-β and IL-10
suppress the production of inflammatory mediators. We found that the expression of these
cytokines was significantly inhibited by VEGF treatment at 16 and 24 h, but were significantly
up-regulated by VEGF at 32 h (Fig. 5A and B).
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3.6. Collectins, the acute-phase reactant SAA, and the antimicrobial protein SMAP29 are
differentially regulated by VEGF in the lung
SP-A and SP-D are members of the collectin family of collagenous proteins with lectin activity
and are produced by respiratory epithelia [35]. These lectins can enhance the clearance of
respiratory pathogens such as RSV [36], and are able to activate macrophage functions [37,
38]. We found that VEGF significantly enhanced SP-A (Fig. 6A) and SP-D (Fig. 6B)
expression at 16 and 32 h after treatment. We also looked at the effects of VEGF administration
on the expression levels of the acute-phase reactant SAA and on the antimicrobial protein
SMAP29. Similarly to GCs [31], VEGF also enhanced the expression of SAA, with an
impressive 6.84-fold increase in animals treated with the high dose VEGF for 16 h (Fig. 6C).
SMAP29, an antimicrobial peptide belonging to the cathelicidin family, has documented
biological activities against respiratory pathogens [39]. Compared to saline-treated animals,
SMAP29 mRNA was decreased in animals treated with VEGF at 16 and 24 h. However, at 32
h, VEGF enhanced the levels of SMAP29 mRNA (Fig. 6D).
3.7. Effect of VEGF on the oxidative responses of lung epithelial cells
The airway epithelial proteins dual oxidase (duox)1 and 2 and the submucosal gland-produced
protein lactoperoxidase (LPO) are important members of a recently described oxidative
pulmonary epithelial host defense system against viruses and bacteria [9–11]. We investigated
the effects of VEGF on these genes and found that duox1 mRNA was induced by VEGF in a
dose-dependent manner at 16 and 32 h (Fig. 7A). Interestingly, the mRNA levels of duox1
were higher at 16 h than at 24 or 32 h. The expression profile of duox2 in response to VEGF
was slightly different from that of duox1: duox2 mRNA levels were significantly decreased
by all doses of VEGF at 24 h. Furthermore, although duox2 mRNA was increased in animals
treated with VEGF at 16 and 32 h, the level of increase was much lower than that of duox1 at
the same time points (Fig. 7B). Animals subjected to the low dose VEGF showed increased
LPO mRNA expression at 16 and 24 h, but not at 32 h. LPO mRNA in animals given the
medium dose of VEGF was undistinguishable from saline-treated animals at 16 and 24 h, but
was significantly decreased at 32 h. Animals subjected to the high dose VEGF for 16 h showed
no difference in LPO mRNA relative to saline-treated animals, while those treated for 24 h
with the same dose VEGF showed significantly decreased LPO mRNA. Finally, those treated
for 32 h showed a significantly increased LPO mRNA (Fig. 7C).
4. Discussion
RDS is a common and devastating disease affecting preterm infants and neonates at a high
incidence [40]. Although symptoms of RDS commonly resolve completely after the acute
phase, the disease may progress severely in some patients [41]. The search for novel agents
that stimulate lung maturation during RDS has pointed at VEGF as a potential candidate [25,
42] which has additional antiviral capabilities [26]. Thus, insights in the role and consequence
of VEGF administration on the host immune response are critical.
In this study, we performed a global gene expression profile analysis in the neonatal ovine lung
to quantitatively measure local in vivo immune responses due to VEGF administration. The
key findings of our study are: (1) despite their immature immune system, newborn lambs
express numerous host defense molecules, including chemokines, pro-inflammatory
mediators, complement proteins, TLRs, anti-inflammatory molecules, antimicrobial proteins,
surfactant proteins (SPs), and genes involved in the epithelial oxidative defense system; (2)
administration of VEGF in the lung of these newborns can enhance the expression of some of
those genes, depending on the dose and duration of VEGF treatment; and (3) VEGF has a
complex mode of action: it can differentially regulate genes with similar functions, and it
possesses some immnunosuppressive effects (enhanced TGF-β and IL-10 at 32 h, reduced IFN-
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β at all time points) along with its immunostimulatory functions. Our findings are partly in
agreement with reports published on the enhancing effects of GCs on the expression of most
epithelial cell genes involved in innate immunity, including TLRs [30,43], surfactant proteins
[31,44], complement [31,45,46], and acute-phase proteins [31]. However, a fundamental
difference between VEGF and GCs is the consistent inhibition of chemokines and
inflammatory cytokines by GCs on airway epithelial cells in vivo and in vitro [31,47–50]. The
reason for the differences can be attributed to the fact that GCs bind the glucocorticoid receptor
and induce immunosuppression through inhibition of cytokine and chemokine gene expression
and prostaglandin synthesis (reviewed in [51]). Although GCs are primarily used in preterm
infants as inducers of surfactant synthesis and not as immunomodulatory agents, recent in
vitro studies have focused on the effects of GCs on the expression of genes involved in the
innate and adaptive immune responses in human peripheral blood mononuclear cells [30] and
on epithelial cells [31]. In addition, recent in vivo studies have looked at the role of VEGF on
lung injury [52] and maturation [52,53] in the mouse model. To our knowledge, our study is
the first systematic attempt to examine the in vivo effects of VEGF on ovine neonatal lung
immune responses.
The expression levels of chemokines, including IL-8, RANTES and MCP-1 mRNA were up-
regulated in VEGF-treated animals compared to control lambs. IL-8 was immediately induced
following the use of the high dose VEGF, suggesting that the up-regulation of IL-8 mRNA is
a direct-effect of VEGF treatment. MCP-1 is a chemokine that can affect the immune response
by recruiting monocytes and macrophages. MCP-1 however did not increase until 32 h after
treatment. This late expression of MCP-1 is likely due to the increased accumulation of
monocytes producing the chemokine, and thus would be an indirect (or secondary) effect of
VEGF. RANTES followed a similar trend in expression as MCP-1. Although VEGF is inducing
the expression of these chemokines, our study does not exclude the possibility that VEGF itself
is acting as a chemotactic factor to recruit cells to the lung, as inflammatory cells such as
monocytes and macrophages express VEGF receptor 1 [54,55].
Among the pro-inflammatory mediators studied, IFN-γ was the most induced cytokine at 32
h. The observed levels of IFN-γ suggest that (1) in addition to macrophages, T cells and/or NK
cells are also recruited to the lung; and (2) VEGF can induce a strong pro-inflammatory
response by activating the cells producing this cytokine. Our observation of elevated TNF-α,
IL-6 and GMCSF levels at 32 h also suggests that these cytokines are produced during cellular
infiltration and may not necessarily be a direct effect of VEGF. Although VEGF enhanced the
expression of many pro-inflammatory mediators, we noticed that, similarly to GCs [30,31],
the VEGF-mediated enhancement of the immune response was accompanied by the inhibition
of the expression of the pro-inflammatory molecule IFN-β, regardless of the dose of VEGF or
the time of treatment. VEGF also enhanced the levels of TGF-β and IL-10 mRNA levels (but
only at 32 h), suggesting an attempt at balancing the effects of other pro-inflammatory
cytokines.
C3, CFB and CFH are members of the complement family of proteins that are essential in
immunity. Previous reports have shown that GCs can enhance the expression of C3 and CFB
[46], as well as CFH [31,45]. Our results show that lambs treated with VEGF for 32 h had
increased levels of these complement factors, further confirming that VEGF enhances immune
responses after treatment.
TLRs are a class of single-membrane spanning receptors that play a key role in the innate
immune system by recognizing specific pathogen associated molecular patterns (PAMPs) at
the surface of invading pathogens and by activating host defense mechanisms. We show that
similarly to GCs [30], VEGF can also induce the expression levels of TLR4. Recent articles
have reported endotoxin effects on TLR4 [56] and on VEGF and VEGFR2 [57] expression.
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Those studies were performed using elevated amounts of endotoxin (10 mg). We do not
attribute the changes in gene expression to endotoxin contamination, as the endotoxin content
in the VEGF recombinant protein was very low (<100 pg/μg). Furthermore, the BSA used in
control animals was not completely endotoxin-free and did not lead to significant changes in
gene expression. Thus, the endotoxin-content of the VEGF recombinant protein has an
independent effect on the mRNA expression of the genes studied.
Surfactant proteins are of particular relevance to RDS and to epithelial innate immune
responses. These proteins are members of the collectin family, characterized by a collagen
domain linked to a calcium-dependent lectin domain [58]. SP-A and SP-D play critical
responses in the lung, including the prevention of alveolar collapse, and the use of opsonization
and aggregation of pathogens such as RSV as a host defense mechanism. Brown et al. have
shown that recombinant VEGF can increase the expression levels of SP-A mRNA in human
fetal lung explants [59]. Other studies have shown that the glucocorticoid dexamethasone can
induce SP-A in rat lung [44]. We observe that ovine SP-A and SP-D can also be induced in
the lung following treatment with VEGF, and that this induction occurs rapidly (at 16 h), and
that the low dose VEGF induces significant levels of SP-A and SP-D mRNA over saline-treated
animals. This suggests that VEGF can act directly and immediately on epithelial cells to induce
the expression of surfactant proteins. Our results are in accord with a recent report showing
that in mice, VEGF induced surfactant production in the newborn and adult lungs, and alveolar
development in the newborn lung [52]. Interestingly, there was also a positive correlation
between VEGF levels in human amniotic fluid and surfactant phospholipids [52]. Studies
performed in mice deficient in macrophage migration inhibitory factor (MIF), an upstream
regulator of innate immune factors such as VEGF, have revealed deficiencies in the expression
of VEGF and surfactant proteins [53].
In addition to collectins, SAA and SMAP29 have important roles in host defense. SAA is an
acute-phase reactant that can be highly induced during the acute-phase response [60]. Of the
21 genes analyzed in this study, SAA was the most induced at 16 h following high dose VEGF
treatment. Interestingly, at that same time point, the low dose VEGF had no effect on SAA
levels, while the medium dose VEGF significantly inhibited SAA mRNA levels. The ovine
cathelicidin SMAP29 showed a time-dependent increase in expression, with the highest levels
observed at 32 h after stimulation. The low dose VEGF was sufficient to induce SMAP29
expression.
We next investigated the effects of VEGF on the NADPH oxidase isoforms duox1 and duox2,
and on the submucosal gland-derived protein lactoperoxidase (LPO). Duox1 mRNA was
rapidly induced by VEGF, and showed a dose-dependent increase at 16 h. Duox1 mRNA
remained elevated (albeit at lower levels than at 16 h) at 24 and 32 h. Duox2 was induced at a
lower level than duox1, and showed a different trend during the time course. The reasons behind
the differences in mRNA levels between duox1 and duox2 are currently unknown, as the
specific roles of these similar proteins are unclear. Interestingly, a recent study reported that
although these two isoforms had 83% sequence similarities, the expression of duox2 mRNA
in human fetal lung epithelial cells was lower than duox1 mRNA, even after treatment with a
glucocorticoid mixture [61]. LPO mRNA was significantly enhanced by the low dose VEGF
at 16 and 24 h, and by the high dose VEGF at 32 h. These studies suggest that VEGF may act
directly on epithelial cells to activate the oxidative response in these cells.
The highest number of genes exhibiting increased mRNA levels was seen at 32 h post VEGF
administration. This could be due to a cascading effect. VEGF receptors are present on several
cell types in the lung, as are receptors for chemokines and cytokines that are triggered by VEGF.
These chemokines and cytokines may trigger the expression of other genes. In addition, VEGF
was administered intrabronchially in this study, and the inoculum delivered in this manner is
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distributed into some, but not all airways and alveoli. With time, there is likely some degree
of VEGF absorption into the pulmonary lymphatic and alveolar capillaries, resulting in
hematogenous distribution more uniformly to the lung parenchyma. Such distribution may
increase the number of cells activated by VEGF and increase overall gene expression.
Intrabronchial delivery was used in this study in order to mimick administration of VEGF via
inhaler or nebulization and to avoid degradation in the blood. In future studies, the effects of
VEGF administered intravenously will be tested. A limitation of the study is the lack of protein
detection because specific antibodies for most targets are not available. Additional experiments
will be performed in the future to understand the direct and indirect effects of VEGF
administration.
GCs are immune suppressors, thus can increase the susceptibility of the host to opportunistic
infections and/or intracellular infections. However, they can be beneficial to the host during a
systemic inflammatory response. VEGF on the other hand acts as an immune-enhancing agent
that also has the ability to inhibit RSV. It is important to keep in mind that the use of VEGF
as a potential therapeutic agent has met concerns of potential adverse effects: transgenic mice
that constitutively express VEGF in the respiratory epithelium had pulmonary lesions and
chronic hemorrhage [62], VEGF caused pulmonary hemosiderosis in newborn and adult
murine lungs by a nitric oxide-dependent mechanism [52], and deposition of high doses (in
high volumes) of VEGF in the lung recruited monocytes and macrophages, and could cause
gross and microscopic lesions [25]. However, the short-term use of lower VEGF doses have
reported minimal clinical complications in sheep [25] and mice [42]. Our findings suggest that
the immuno-enhancing activities of VEGF might have a therapeutic potential for lung
maturation in infants at risk for RDS. Further studies on the effects of VEGF in preterm lambs
as well as lambs suffering from RDS may identify yet additional effects on lung immunity.
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Fig. 1.
VEGF induces chemokines gene expression. IL-8 (A), RANTES (B) and MCP-1 (C) mRNA
levels in homogenized lungs of full-term lambs were determined by real-time qPCR. The
chemokines mRNA expression levels were expressed as fold induction relative to saline-treated
lambs. The data represent the mean ± SEM (n = 3 for saline; for low dose VEGF n = 1 at all
time points; for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h; for high dose
VEGF, n = 1 for all time points; for BSA, n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 by ANOVA
when compared to saline-treated animals.
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Fig. 2.
Pro-inflammatory mediators are induced by VEGF. IFN-γ (A), IL-6 (B), TNF-α (C), IFN-β
(D), and GMCSF (E) mRNA levels in homogenized lungs of full-term lambs were determined
by real-time qPCR. The mRNA expression levels were expressed as fold induction relative to
saline-treated lambs. The data represent the mean ± SEM (n = 3 for saline; for low dose VEGF
n = 1 at all time points; for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h;
for high dose VEGF, n = 1 for all time points; for BSA, n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤
0.001 by ANOVA when compared to saline-treated animals.
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Fig. 3.
Complement is also induced in the lung of VEGF-treated lambs. C3 (A), CFB (B), and CFH
(C) mRNA levels in homogenized lungs of full-term lambs were determined by real-time
qPCR. The mRNA expression levels were expressed as fold induction relative to saline-treated
lambs. The data represent the mean ± SEM (n = 3 for saline; for low dose VEGF n = 1 at all
time points; for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h; for high dose
VEGF, n = 1 for all time points; for BSA, n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 by ANOVA
when compared to saline-treated animals.
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Fig. 4.
Effects of VEGF treatment on TLR expression. TLR4 mRNA levels in homogenized lungs of
full-term lambs were determined by real-time qPCR. The mRNA expression levels were
expressed as fold induction relative to saline-treated lambs. The data represent the mean ± SEM
(n = 3 for saline; for low dose VEGF n = 1 at all time points; for medium dose VEGF n = 2
for 16 h, n = 3 for 24 h, n = 2 for 32 h; for high dose VEGF, n = 1 for all time points; for BSA,
n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 by ANOVA when compared to saline-treated animals.
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Fig. 5.
Anti-inflammatory cytokines are also up-regulated by VEGF treatment. TGF-β (A) and IL-10
(B) mRNA levels mRNA levels in homogenized lungs of full-term lambs were determined by
real-time qPCR. The mRNA expression levels were expressed as fold induction relative to
saline-treated lambs. The data represent the mean ± SEM (n = 3 for saline; for low dose VEGF
n = 1 at all time points; for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h;
for high dose VEGF, n = 1 for all time points; for BSA, n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤
0.001 by ANOVA when compared to saline-treated animals.
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Fig. 6.
Collectins and the host defense molecules SAA and SMAP29 are induced by VEGF. SP-A
(A), SP-D (B), SAA (C) and SMAP29 (D) mRNA levels in homogenized lungs of full-term
lambs were determined by real-time qPCR. The mRNA expression levels were expressed as
fold induction relative to saline-treated lambs. The data represent the mean ± SEM (n = 3 for
saline; for low dose VEGF n = 1 at all time points; for medium dose VEGF n = 2 for 16 h, n
= 3 for 24 h, n = 2 for 32 h; for high dose VEGF, n = 1 for all time points; for BSA, n =
2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 by ANOVA when compared to saline-treated animals.
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Fig. 7.
Effects of VEGF on epithelial cells oxidative responses. duox1 (A), duox2 (B), and LPO (C)
mRNA levels in homogenized lungs of full-term lambs were determined by real-time qPCR.
The mRNA expression levels were expressed as fold induction relative to saline-treated lambs.
The data represent the mean ± SEM (n = 3 for saline; for low dose VEGF n = 1 at all time
points; for medium dose VEGF n = 2 for 16 h, n = 3 for 24 h, n = 2 for 32 h; for high dose
VEGF, n = 1 for all time points; for BSA, n = 2). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 by ANOVA
when compared to saline-treated animals.
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Table 1
List of primers/probes used for real-time qPCR.
Primer name Sequence (5′–3′)
GenBank Accession number or
source
IL-8 forward TTCCAAGCTGGCTGTTGCT X78306
IL-8 reverse TTGACAGAACTGCAGCTTCACA
IL-8 probe FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA
RANTES forward TGCTTCTGCCTCCCCATATG Based on alignment of conserved
sequences between human
(NM_002985) and bovine
(NM_175827) RANTES
RANTES reverse GGGCGGGAGATATAGGCAAA
RANTES probe FAM-CACCACGCCCTGCT-MGBNFQ
MCP-1 forward GCTGTGATTTTCAAGACCATCCT Based on conserved sequences
reported in [28]
MCP-1 reverse GGCGTCCTGGACCCATTT
MCP-1 probe FAM-AAAGAGTTTTGTGCAGACCCCAACC-TAMRA
IFN-γ forward TGGAGGACTTCAAAAGGCTGAT NM_001009803
IFN-γ reverse GATGGCTTTGCGCTGGAT
IFN-γ probe FAM-CAAATTCCGGTGGATGATCTGC-TAMRA
IL-6 forward GCTGCTCCTGGTGATGACTTC NM_001009392
IL-6 reverse GGTGGTGTCATTTTTGAAATCTTCT
IL-6 probe FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ
TNF-α forward CAACCTGGGACACCCAGAAT NM_001024860
TNF-α reverse TCTCAAGGAACGTTGCGAAGT
TNF-α probe FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA
IFN-β forward TGGTTCTCCTGCTGTGTTTCTC NM_174350
IFN-β reverse CGTTGTTGGAATCGAAGCAA
IFN-β probe FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA
GMCSF forward CCCTGGCAGCTTGTGGAT EU287484
GMCSF reverse GTGTCAGTGCTGTCGTTCAGAAG
GMCSF probe FAM-CCATCAAGGAGGCCCT-MGBNFQ
C3 forward GGACACCAGGGAGAAAGATGTG AF038130
C3 reverse CGTGCAGCGCGATCAG
C3 probe FAM-CCCTTACAGCCTTTG-MGBNFQ
CFB forward GGCCCCCTGATTATTCACAA EF446375
CFB reverse CAGCTGATCACGCCAACTTG
CFB probe FAM-AGGAGCCGCTTCAT-MGBNFQ
CFH forward CGGTGTCAGGCCTACTATGAACT EU888587
CFH reverse GGTTCTGACCACTCTCCATTCC
CFH probe FAM-AGGGAAACAGAAACGTAGTAT-MGBNFQ
TLR4 forward CCATCGCCGCCAATATCA DQ922636
TLR4 reverse TGGGACACCACGACAATAACC
TLR4 probe FAM-CCAGGAGGGTTTCCACAAAAGCCGT-TAMRA
TGF-β forward TGT GTT CGT CAG CTC TAC ATT GAC NM_001009400
TGF-β reverse TAG CCC TTG GGT TCG TGA AT
TGF-β probe FAM-TCC AGC CCA GGT CCT TCC GGA-TAMRA
IL-10 forward GTCGGAAATGATCCAGTTTTACCT Z29362
IL-10 reverse GTCAGGCCCATGGTTCTCA
IL-10 probe FAM-AGGAGGTGATGCCACAGG-MGBNFQ
SP-A forward TGACCCTTATGCTCCTCTGGAT AF076633
SP-A reverse GGGCTTCCAAGACAAACTTCCT
SP-A probe FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA
SP-D forward ACGTTCTGCAGCTGAGAAT AJ133002
SP-D reverse TCGGTCATGCTCAGGAAAGC
SP-D probe FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA
SAA forward GGGACGAGGTACGGAAGGAT EU366476
SAA reverse TCCGGCCCCATTCGTT
SAA probe FAM-CGAAGGCCGACCAGT-MGBNFQ
SMAP29 forward GGCCCAACTGTTCTCCGAAT L46854
SMAP29 reverse GCAGACCCTTAGGACTCTTTCCT
SMAP29 probe FAM-ATCAGAATAGCTGGGTGAATTGTGGGCC-TAMRA
Duox1 forward AGCCGGGCTGAGTTTGC XM_587550
Duox1 reverse AACATGGACTGCACAAACATGTC
Duox1 probe FAM-AGTCCCTGGGCCTCAAGCCCC-TAMRA
Duox2 forward GCCCCAGGACATGTTTGTG Based on conserved sequences
between human (NM_014080)
and sus scrofa (NM_213999) at
the codon level
Duox2 reverse GCCATTGCCATCCTTGTCA
Duox2 probe FAM-AGTCCATGTTCTCTCTG-MGBNFQ
LPO forward AAGCAGCGGGACTCTCTACAGA NM_001009722
LPO reverse GACCTTCGTGATGTGGGTGTT
LPO probe FAM-CCTTCTCGCGCCTCA-MGBNFQ
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Primer name Sequence (5′–3′)
GenBank Accession number or
source
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